Valeant Pharma (VRX): Yet Another Guidance Cut - Jefferies
Get Alerts VRX Hot Sheet
Rating Summary:
0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 11
Join SI Premium – FREE
Jefferies analyst, David Steinberg, reiterated his Buy rating on shares of Valeant Pharmaceuticals (NYSE: VRX) but cut his price target nearly in half to $22 from $40. While Q3 revs of $2.444B were just slightly (0.7%) below his est, EPS came in well below consensus ($1.55 vs $1.75) due to product mix & higher interest expense.
However, guidance was the focal point and lowered once again. The analyst thinks the biggest surprise was management's commentary that FY17 revs & EBITDA will be lower than current FY16 guidance. Management claims divestitures are not needed to maintain liquidity but will likely be key to NT performance.
For an analyst ratings summary and ratings history on Valeant Pharmaceuticals click here. For more ratings news on Valeant Pharmaceuticals click here.
Shares of Valeant Pharmaceuticals closed at $14.98 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Teleperformance (TEP:FP) (TLPFY) PT Lowered to EUR125 at RBC Capital, 'perceived risk profile makes it a no-fly zone for many investors'
- Cintas (CTAS) PT Raised to $790 at UBS
- UPS (UPS) PT Lowered to $150 at HSBC, 'on lower multiple to reflect continued de-rating'
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst PT Change, EarningsRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!